RxDoctor Payments Data

Megha Patel

Physician Assistant · Daytona Beach, FLNPI 1679117725

Payments from drug & device makers

$5,610in general payments, 2019–2025

Across 157 payments — averaging $35.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$1K
  • Pfizer$637
  • Dendreon Pharmaceuticals LLC$540
  • Johnson & Johnson$435
  • AstraZeneca$383
  • AbbVie$284
  • plus $2K from 27 others

What the payments were for

  • Consulting fees$90416%
  • Speaking & faculty fees$3606%
  • Food & beverage$3,99271%
  • Education$3546%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,610 in reported general payments places this provider in the 90th percentile of 8,062 physician assistant providers in Florida.

See all physician assistant providers in Florida

Medicare billing

Part B allowed, 2024
$75,521
Medicare patients
435
Services billed
1,521

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide87$1,199,808
ErleadaApalutamide74$1,031,020
OrgovyxRelugolix54$146,824
MyrbetriqMirabegron86$66,460
Abiraterone Acetate40$46,169
Tamsulosin Hcl289$4,145
Solifenacin Succinate124$3,506
Methenamine Hippurate34$2,006
Testosterone Cypionate38$1,992
Estradiol31$1,834
Alfuzosin Hcl ErAlfuzosin Hcl70$1,487
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst80$1,342
Silodosin14$1,159
Tadalafil19$1,010
Desmopressin Acetate15$818

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$151$1,266,268173 claims
Johnson & JohnsonErleada$435$1,031,02074 claims
Sumitomo Pharma America, Inc.Orgovyx$80$146,82454 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,062 physician assistant providers in Florida.

Other physician assistant in Daytona Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →